NEW YORK (360Dx) – T2 Biosystems announced today that its has filed a 510(k) premarket submission for its T2Bacteria Panel with the US Food and Drug Administration.

The panel runs on the FDA-cleared T2Dx instrument and is designed to be a comprehensive rapid diagnostic test that identifies pathogens associated with sepsis within hours instead of days, T2 Biosystems said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.